Financial Survey: Alpha Tau Medical (NASDAQ:DRTS) versus Beyond Air (NASDAQ:XAIR)

Alpha Tau Medical (NASDAQ:DRTS) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Risk & Volatility

Alpha Tau Medical has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Beyond Air has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500.

Earnings & Valuation

This table compares Alpha Tau Medical and Beyond Air”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$29.16 million	($0.40)	-5.70
Beyond Air	$1.16 million	18.10	-$60.24 million	($1.64)	-0.27

Alpha Tau Medical has higher earnings, but lower revenue than Beyond Air. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alpha Tau Medical and Beyond Air’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-33.75%	-26.78%
Beyond Air	-3,272.46%	-240.15%	-109.38%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Alpha Tau Medical and Beyond Air, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	0	0	3	0	3.00
Beyond Air	0	1	3	1	3.00

Alpha Tau Medical presently has a consensus price target of $8.00, indicating a potential upside of 250.88%. Beyond Air has a consensus price target of $3.67, indicating a potential upside of 723.97%. Given Beyond Air’s higher possible upside, analysts plainly believe Beyond Air is more favorable than Alpha Tau Medical.

Institutional and Insider Ownership

2.7% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by insiders. Comparatively, 19.0% of Beyond Air shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Alpha Tau Medical beats Beyond Air on 7 of the 12 factors compared between the two stocks.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

About Beyond Air

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.